Sanofi/$SNY

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Sanofi

Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for approximately 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.

Ticker

$SNY
Sector
Primary listing

Employees

82,878
Headquarters

Sanofi Metrics

BasicAdvanced
$120B
5.77
$8.53
0.44
$1.60
3.25%

What the Analysts think about Sanofi

Analyst ratings (Buy, Hold, Sell) for Sanofi stock.

Bulls say / Bears say

Sanofi raised its annual sales growth outlook to a high single-digit percentage, citing strong global demand for Dupixent, and confirmed its guidance for low double-digit earnings growth.
In Q1 2025, Sanofi’s business operating income climbed 20.1% to €2.90 billion, beating analyst estimates thanks to a 20.3% increase in Dupixent sales and 54.9% growth in its newborn respiratory treatment Beyfortus.
Sanofi agreed to acquire Blueprint Medicines for up to $9.5 billion, strengthening its rare immunology portfolio with Ayvakit and boosting its pipeline with candidates such as elenestinib and BLU-808.
Sanofi’s shares dropped more than 9% in September 2025 after Phase III trial results for its experimental inflammation drug amlitelimab fell short compared to Dupixent, increasing worries about the company's pipeline after Dupixent's patent expires in 2031.
Even with strong Dupixent sales, Sanofi’s business operating income in Q2 2025, excluding one-time items, rose only 3.3% to €2.46 billion, missing analyst expectations and signaling margin pressures from higher profit-sharing and R&D expenses.
Possible U.S. sector tariffs and ongoing national security probes into pharmaceutical imports could drive up Sanofi’s production costs and disrupt supplies to its largest market.
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.

Sanofi Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Sanofi Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SNY

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs
Buy Sanofi stock | $SNY Share Price | Lightyear